Skip to main content
SpringerLink
Log in

Clinical studies with letrozole

  • Chapter
Aromatase Inhibitors

Part of the book series: Milestones in Drug Therapy MDT ((MDT))

  • 296 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Imaginis Corporation. At: http://www.imaginis.com/breasthealth/statistics.asp. Accessed May 31, 2005

    Google Scholar 

  2. Ferlay J, Bray F, Pisani P, Parkin DM (2001) GLOBOCAN 2000. IARC Press, Lyon, France

    Google Scholar 

  3. Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 351: 1451–1467

    Google Scholar 

  4. Dowsett M (1992) Rationale for the endocrine treatment of breast cancer. In: Dowsett M (ed.): Endocrine Aspects of Breast Cancer. Parthenon Publishing Group, Camforth, England, 11–24

    Google Scholar 

  5. Buzdar AU (1990) Current status of endocrine treatment of carcinoma of the breast. Semin Surg Oncol 6: 77–82

    CAS  PubMed  Google Scholar 

  6. Masamura S, Adlercreutz H, Harvey H, Lipton A, Demers LM, Santen RJ, Santner SJ (1995) Aromatase inhibitor development for treatment of breast cancer. Breast Cancer Res Treat 33: 19–26

    Article  CAS  PubMed  Google Scholar 

  7. Lønning P, Pfister C, Martoni A, Zamagni C (2003) Pharmacokinetics of third-generation aromatase inhibitors. Semin Oncol 30(Suppl 14): 23–32

    PubMed  Google Scholar 

  8. Grodin JM, Siiteri PK, MacDonald PC (1973) Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab 36: 207–214

    CAS  PubMed  Google Scholar 

  9. Goldhirsch A, Gelber RD (1996) Endocrine therapies in breast cancer. Semin Oncol 23: 494–505

    CAS  PubMed  Google Scholar 

  10. Bhatnagar AS, Hausler A, Schieweck K, Lang M, Bowman R (1990) Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. J Steroid Biochem Mol Biol 37: 1021–1027

    CAS  PubMed  Google Scholar 

  11. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd L, Pritchard KI et al. (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349: 793–802

    Article  Google Scholar 

  12. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ et al. (2004) Updated analysis of the NCIC CTG MA.17 randomized placebo controlled trial of letrozole after five years of tamoxifen in postmenopausal women with early stage breast cancer. Proc Am Soc Clin Oncol 22: 87 (abstract 847)

    Google Scholar 

  13. Gershanovich M, Chaudri HA, Campos D, Lurie H, Bonaventura A, Jeffrey M, Buzzi F, Bodrogi I, Ludwig H, Reichardt P et al. for the Letrozole International Trial Group (AR/BC3) (1998) Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Ann Oncol 9: 639–645

    Article  CAS  PubMed  Google Scholar 

  14. Rose C, Vtoraya O, Pluzanska A, Davidson N, Gershanovich M, Thomas R, Johnson S, Caicedo JJ, Gervasio H, Manikhas G et al. (2003) An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 39: 2318–2327

    Article  CAS  PubMed  Google Scholar 

  15. Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, Mauriac L, Ellis M, Lassus M, Chaudri-Ross HA et al. (2001) Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized, double-blind, multicenter study. Ann Oncol 12: 1527–1532

    CAS  PubMed  Google Scholar 

  16. [http://www.ibcsg.org/public/documents/pdf/divers/BIG_1-98_ASCO_2005_Final.pdf]. Accessed June 2, 2005

    Google Scholar 

  17. Mouridsen H, Gershanovich M, Sun Y, Pérez-Carrión R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jänicke F et al. (2003) Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Group. J Clin Oncol 21: 2101–2109

    Article  CAS  PubMed  Google Scholar 

  18. Mouridsen H, Gershanovich M, Sun Y, Pérez-Carrión R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jänicke F et al. (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Group. J Clin Oncol 19: 2596–2606

    CAS  PubMed  Google Scholar 

  19. Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M et al. (1998) Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16: 453–461

    CAS  PubMed  Google Scholar 

  20. Geisler J, Haynes B, Anker G, Dowsett M, Lönning PE (2002) Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20: 751–757

    Article  CAS  PubMed  Google Scholar 

  21. Dixon JM, Love CD, Bellamy CO, Cameron DA, Leonard RC, Smith H, Miller WR (2001) Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat 66: 191–199

    Article  CAS  PubMed  Google Scholar 

  22. Data on file. Novartis Pharmaceuticals Corporation

    Google Scholar 

  23. Ellis MJ, Coop A, Singh B, Mauriac L, Lombert-Cussac A, Jänicke F, Miller WR, Evans DB, Dugan M, Brady C et al. (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19: 3808–3816

    CAS  PubMed  Google Scholar 

  24. Allred DC, Harvey JM, Bernardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11: 155–168

    CAS  PubMed  Google Scholar 

  25. Renshaw L, Murray J, Young O, Cameron D, Miller WR, Dixon JM (2004) Is there an optimal duration of neoadjuvant letrozole therapy. Breast Cancer Research and Treatment; in press

    Google Scholar 

  26. Wasan KM, Goss PE, Pritchard PH, Shepherd L, Palmer MJ, Liu S, Tu D, Ingle JN, Heath M, Deangelis D, Perez EA (2005) The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol 16: 707–715

    Article  CAS  PubMed  Google Scholar 

  27. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS; ATAC Trialists’ Group (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365: 60–62

    Article  CAS  PubMed  Google Scholar 

  28. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O et al. (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350: 1081–1092

    Article  CAS  PubMed  Google Scholar 

  29. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Brown S (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21: 4042–4057

    CAS  PubMed  Google Scholar 

  30. Brufsky A, Harker G, Beck T, Carroll R, Tan-Chiu E, Seidler C, Lacema L, Thomas E, Perez E; Z-FAST Study Group (2004) Zoledronic acid (ZA) for prevention of cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (Let): Preliminary results of the Z-FAST trial. Breast Cancer Res Treat 88: S233 (abstract 6038)

    Google Scholar 

  31. Saphner T, Tormey DC, Gray R (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14: 2738–2746

    CAS  PubMed  Google Scholar 

  32. Hortobagyi GN, Kau S-W, Buzdar AU, Theriault RL, Booser DJ, Gwyn K, Valero V (2004) What is the prognosis of patients with operable breast cancer (BC) five years after diagnosis? Proc Am Soc Clin Oncol 22: (abstract 585)

    Google Scholar 

  33. Fisher B, Dignam J, Bryant J, Wolmark N (2001) Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93: 684–690

    CAS  PubMed  Google Scholar 

  34. Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Tu D, Goss PE (2004) Effect of letrozole versus placebo on bone mineral density in women completing 5 years (yrs) of adjuvant tamoxifen: NCIC CTG MA.17B. Breast Cancer Res Treat 88: S36 (abstract 404)

    Google Scholar 

  35. Whelan T, Goss P, Ingle J, Pater J, Shepherd L, Palmer D, Tu D, Robert N, Martino S, Muss H et al. (2004) Assessment of quality of life (QOL) in MA.17, a randomized placebo-controlled trial of letrozole in postmenopausal women following five years of tamoxifen. Proc Am Soc Clin Oncol 23: 6 (abstract 517)

    Google Scholar 

  36. Femara Prescribing Information (2003) East Hanover, NJ: Novartis Pharmaceuticals Corporation

    Google Scholar 

  37. Mouridsen HT, Rose C, Brodie AH, Smith IE (2003) Challenges in the endocrine management of breast cancer. Breast 12(Suppl 2): S2–S19

    PubMed  Google Scholar 

  38. Buzdar A, Douma J, Davidson N, Elledge R, Morgan M, Smith R, Porter L, Nabholtz J, Xiang X, Brady C (2001) Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 19: 3357–3366

    CAS  PubMed  Google Scholar 

  39. Wright C, Nicholson S, Angus B, Sainsbury JR, Farndon J, Cairns J, Harris AL, Horne CH (1992) Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65: 118–121

    CAS  PubMed  Google Scholar 

  40. Yamauchi H, O’Neill A, Gelman R, Carney W, Tenney DY, Hosch S, Hayes DF (1997) Prediction of response to antiestrogen therapy in advanced breast cancer patients by pre-treatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 15: 2518–2525

    CAS  PubMed  Google Scholar 

  41. Berns EM, Foekens JA, van Staveren IL, van Putten WL, de Koning HY, portengen H, Klijn JO (1995) Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment. Gene 159: 11–18

    Article  CAS  PubMed  Google Scholar 

  42. Archer SG, Eliopoulos A, Spandidos D, Barnes D, Ellis IO, Blamey RW, Nicholson RI, Robertson JF (1995) Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer 72: 1259–1266

    CAS  PubMed  Google Scholar 

  43. Newby JC, Johnston SR, Smith IE, Dowsett M (1997) Expression of epidermal growth factor receptor and c-erb-B2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 3: 1643–1651

    CAS  PubMed  Google Scholar 

  44. Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A, Pettinato G, Panico L, D’Antonio A, Bianco AR, De Placido S (1996) c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 14: 2702–2708

    CAS  PubMed  Google Scholar 

  45. Lipton A, Ali SM, Leitzel K, Chinchilli V, Engle L, Demers L, Brady C, Carney W, Cook G et al. (2000) Elevated serum Her-2/neu predicts decreased response to hormone therapy in metastatic breast cancer. Proc Am Soc Clin Oncol 19: 1a (abstract 274)

    Google Scholar 

  46. Benz CC, Scott GK, Sarup JC et al. (1993) Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24: 85–95

    CAS  PubMed  Google Scholar 

  47. Lee H, Jiang F, Wang Q, Nicosia SV, Yang J, Su B, Bai W (2000) MEKK1 activation of human oestrogen receptor alpha and stimulation of the agonistic activity of 4-hydroxytamoxifen in endometrial and ovarian cancer cells. Mol Endocrinol 14: 1882–1896

    CAS  PubMed  Google Scholar 

  48. Lupu R, Lippman ME (1993) The role of erbB2 signal transduction pathways in human breast cancer. Breast Cancer Res Treat 27: 83–93

    Article  CAS  PubMed  Google Scholar 

  49. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A et al. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707–712

    CAS  PubMed  Google Scholar 

  50. Clark GM, McGuire WL (1991) Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 51: 944–948

    CAS  PubMed  Google Scholar 

  51. Young O, Murray J, Renshaw L, Evans D, Cameron D, Dowsett M, Miller WR, Dixon JM (2004) Her2 status does not influence response to neoadjuvant letrozole. Breast Cancer Research and Treatment 88(Suppl 1): S38

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Edinburgh Breast Unit, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK

    J. Michael Dixon

Authors
  1. J. Michael Dixon
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. AstraZeneca, Global Discovery, Mereside, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK

    Barrington J.A. Furr

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Birkhäuser Verlag/Switzerland

About this chapter

Cite this chapter

Dixon, J.M. (2006). Clinical studies with letrozole. In: Furr, B.J. (eds) Aromatase Inhibitors. Milestones in Drug Therapy MDT. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7418-7_5

Download citation

Publish with us

Policies and ethics

Search

Navigation